Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Akoya Biosciences Inc (NASDAQ: AKYA) was $3.02 for the day, up 7.09% from the previous closing price of $2.82. In other words, the price has increased by $7.09 from its previous closing price. On the day, 0.8 million shares were traded. AKYA stock price reached its highest trading level at $3.05 during the session, while it also had its lowest trading level at $2.755.
Ratios:
Our analysis of AKYA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.85 and its Current Ratio is at 2.75. In the meantime, Its Debt-to-Equity ratio is 6.23 whereas as Long-Term Debt/Eq ratio is at 5.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Craig Hallum on November 15, 2024, Downgraded its rating to Hold and sets its target price to $5 from $7 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 11 ’24 when McKelligon Brian sold 7,500 shares for $2.08 per share. The transaction valued at 15,630 led to the insider holds 224,733 shares of the business.
McKelligon Brian sold 7,500 shares of AKYA for $15,064 on Jun 06 ’24. The President and CEO now owns 224,733 shares after completing the transaction at $2.01 per share. On Mar 20 ’24, another insider, McKelligon Brian, who serves as the President and CEO of the company, sold 7,500 shares for $4.97 each. As a result, the insider received 37,243 and left with 231,868 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKYA now has a Market Capitalization of 149709552 and an Enterprise Value of 194407392. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.72 while its Price-to-Book (P/B) ratio in mrq is 10.97. Its current Enterprise Value per Revenue stands at 2.086 whereas that against EBITDA is -4.923.
Stock Price History:
The Beta on a monthly basis for AKYA is 1.21, which has changed by -0.43030304 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, AKYA has reached a high of $6.31, while it has fallen to a 52-week low of $1.88. The 50-Day Moving Average of the stock is 19.89%, while the 200-Day Moving Average is calculated to be 10.64%.
Shares Statistics:
AKYA traded an average of 586.88K shares per day over the past three months and 2349890 shares per day over the past ten days. A total of 49.57M shares are outstanding, with a floating share count of 49.57M. Insiders hold about 0.00% of the company’s shares, while institutions hold 24.59% stake in the company. Shares short for AKYA as of 1730332800 were 1601700 with a Short Ratio of 2.98, compared to 1727654400 on 2355998. Therefore, it implies a Short% of Shares Outstanding of 1601700 and a Short% of Float of 5.3400002.
Earnings Estimates
The current assessment of Akoya Biosciences Inc (AKYA) involves the perspectives of 5.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.2 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.91 and -$1.15 for the fiscal current year, implying an average EPS of -$1.07. EPS for the following year is -$0.62, with 5.0 analysts recommending between -$0.44 and -$0.71.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $22.91M to a low estimate of $20.2M. As of the current estimate, Akoya Biosciences Inc’s year-ago sales were $26.49MFor the next quarter, 7 analysts are estimating revenue of $19.97M. There is a high estimate of $21M for the next quarter, whereas the lowest estimate is $17.9M.
A total of 8 analysts have provided revenue estimates for AKYA’s current fiscal year. The highest revenue estimate was $83.2M, while the lowest revenue estimate was $80.5M, resulting in an average revenue estimate of $81.9M. In the same quarter a year ago, actual revenue was $96.63MBased on 8 analysts’ estimates, the company’s revenue will be $91.58M in the next fiscal year. The high estimate is $93.86M and the low estimate is $89M.
